Edgewise Therapeutics (US.EWTX)
Capital Allocation Audit · Period: 2019 – 2026
Key Metrics
US.EWTX · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.6% | → |
| ROE | -9.9% | → |
| Cash Conversion | - | → |
| D/E Ratio | 0.01 | ↑ |
| Gross Margin | - | → |
US.EWTX (Edgewise Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.6% → ROE -9.9% → Cash Conversion - → D/E Ratio 0.01 ↑ Gross Margin - →
Key Metrics
US.EWTX (Edgewise Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.6% →ROE -9.9% →Cash Conversion - →D/E Ratio 0.01 ↑Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies